Intracellular immunization against SIVmac utilizing a hairpin ribozyme

Virology
M HeuschF Wong-Staal

Abstract

A hairpin ribozyme targeting the 3' LTR region (9456) of SIVmac238 was cloned into a murine retroviral vector. This target sequence is conserved among various SIV, as well as most HIV-2, strains. The ribozyme cassette is driven from a polymerase III promoter, that of the human tRNAval gene. Hybrid human B-/T-cell lines (CEM/174) were transduced with the retroviral constructs and selected for G418 resistance. Cells stably expressing the 9456 ribozyme exhibited long-term resistance to infection by a pathogenic molecular clone of SIV and two strains of HIV-2. The ribozyme was also able to effectively reduce the proviral DNA burden. Its efficient protection against SIV/HIV-2 infection constitutes an important step toward evaluating ribozyme gene therapy in a primate model.

Citations

Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·E PoeschlaF Wong-Staal
Jun 1, 1996·Journal of Medical Primatology·M RosenzweigR P Johnson
May 17, 2003·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·David SteeleGarrett A Soukup
Aug 1, 1997·Molecular Biotechnology·A Menke, G Hobom
Nov 20, 1998·Current Opinion in Biotechnology·P J WelchF Wong-Staal

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.